m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05425
 [1]
m6A modification LNCAROD LNCAROD METTL3 Methylation : m6A sites Direct Enhancement Non-coding RNA LNCAROD YBX1  lncRNA       miRNA   circRNA
m6A Modification:
m6A Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
m6A Target LncRNA activating regulator of DKK1 (LNCAROD)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator LncRNA activating regulator of DKK1 (LNCAROD) LncRNA View Details
Regulated Target Y-box-binding protein 1 (YBX1) View Details
Crosstalk Relationship m6A  →  ncRNA Enhancement
Crosstalk Mechanism m6A regulators directly modulate the functionality of ncRNAs through specific targeting ncRNA
Crosstalk Summary The N6-methyladenosine (m6A) modification mediated by METTL3 and METTL14 enhanced the stability of LncRNA activating regulator of DKK1 (LNCAROD) in head and neck squamous cell carcinoma cells. LNCAROD is stabilized by m6A methylation and promotes cancer progression via forming a ternary complex with HSPA1A and Y-box-binding protein 1 (YBX1) in head and neck squamous cell carcinoma.
Responsed Disease Head and neck squamous carcinoma ICD-11: 2B6E
 Disease Info 
Pathway Response Proteasome hsa03050
Cell Process Proteasomal degradation
In-vitro Model
 HK1 Nasopharyngeal carcinoma Acipenser baerii CVCL_YE27
FaDu Hypopharyngeal squamous cell carcinoma Homo sapiens CVCL_1218
Tca8113 Endocervical adenocarcinoma Homo sapiens CVCL_6851
CAL-27 Tongue squamous cell carcinoma Homo sapiens CVCL_1107
NP69SV40T
 N.A. Homo sapiens CVCL_F755
C666-1 Nasopharyngeal carcinoma Homo sapiens CVCL_7949
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
2B6E: Head and neck squamous carcinoma 3 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name OraTest Approved [2]
External Link
TTD: D00DCY
 Compound Name Contusugene ladenovec Phase 3 [3]
Synonyms
Advexin; Ad5CMV-p53; INGN-004; INGN-201; Ad-p53, Introgen; Gene therapy (p53/adenovirus), University of Texas; Gene therapy (p53/adenoviral), Introgen/Aventis; Gene therapy (p53/adenoviral), Introgen/RPR
    Click to Show/Hide
External Link
TTD: D04FYL
 Compound Name INGN-234 Discontinued in Phase 2 [4]
Synonyms
P53 tumor suppressor (topical formulation), Introgen
    Click to Show/Hide
External Link
TTD: D05AHK
References
Ref 1 LNCAROD is stabilized by m6A methylation and promotes cancer progression via forming a ternary complex with HSPA1A and YBX1 in head and neck squamous cell carcinoma. Mol Oncol. 2020 Jun;14(6):1282-1296. doi: 10.1002/1878-0261.12676. Epub 2020 Apr 13.
Ref 2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 3 ClinicalTrials.gov (NCT00041613) Study to Compare the Overall Survival of Patients Receiving INGN 201 (Study Drug) With Patients Receiving Methotrexate. U.S. National Institutes of Health.
Ref 4 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028790)